Dedicated to
Breaking Through

At Libra Therapeutics, we’re taking a new approach to fighting neurodegeneration and meeting one of health’s greatest needs.

Our Life’s Work Is to Find Better Treatments

We’ve experienced first-hand the debilitating effects of neurodegeneration, and we’re dedicated to doing our part by leading new perspectives and meaningful breakthroughs in drug development for these devastating diseases.

OUR TEAM

Leadership

Shawn Scranton, PharmD

Chief Executive Officer & President, Libra Therapeutics
Martin Gill, PhD

Chief Scientific Officer
Dr. Gill joined Libra Therapeutics in 2021 and has played a central role in advancing the company’s small molecule portfolio from high-throughput screening into clinical development. Prior to joining Libra, he served as Head of In Vitro Discovery at Neuropore Therapies, where he led efforts to identify and advance small molecule mechanisms that reduce CNS inflammation and protein pathology associated with PD and ALS. Earlier in his career, at Bristol Myers Squibb, Dr. Gill led programs targeting pathogenic mechanisms of neurodegeneration and genetically defined diseases. He received his Ph.D. from the University of Texas Medical Branch, his B.A. from the University of Missouri-Columbia, and completed postdoctoral fellowships at Northwestern University Feinberg School of Medicine and Eli Lilly and Company.

Board of Directors

Shawn Scranton, PharmD

Chief Executive Officer & President, Libra Therapeutics
Casey Cunningham, MD

Partner and Chief Scientific Officer of Santé Ventures
Fei Shen, PhD

Managing Director
Boehringer Ingelheim Venture Fund USA
Gene Kinney, PhD

Chairman of the Board, Libra Therapeutics
President and Chief Executive Officer, Prothena
Lin Ning, PhD

Senior Associate
Dolby Family Ventures
Board observer
Stefan Lohmer, PhD

Founder and Chief Executive Officer, AXXAM
Lori Gough, PhD

Partner, Epidarex Capital
Daguang Wang, PhD

Managing Director
Yonjin Venture LLC

Scientific Advisory Board

Don Cleveland, PhD

Professor, Molecular and Cell Medicine
Head, Laboratory of Cell Biology, UCSD
Ludwig Institute for Cancer Research
John Ravits, MD

Professor of Clinical Neurosciences
Department of Neuroscience, UCSD
John Renger, PhD

Chief Science Officer, Cerevel Therapeutics
Clotilde Lagier Tourenne, MD, PhD

Assistant Professor of Neurology, MGH, Harvard
Associate Member of the Broad Institute

Shape the Future
of the Mind

Join a highly experienced, passionate team discovering novel ways to change the outcome for millions.

If you share a passion for neuroscience, drug discovery and ultimately, having a dramatic impact on improving patient lives or to apply for an open position, please email opportunities@libratherapeutics.com and provide a CV/resume and statement of interest.

Have Questions?

Restoring a Disrupted
Equilibrium

We’re developing novel therapeutics capable of increasing the body’s natural ability to break down and clear away aggregated proteins and dysfunctional organelles, while also inhibiting key biological mechanisms that contribute to ALS and other degenerative disorders.

The result is an essential return to balance within the body.

VIEW OUR PIPELINE

Dedicated to Breaking Through